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Introduction
India is among a few developing countries to succeed in building strong local capability in the technology-intensive pharmaceutical sector 1 . Presently Indian pharmaceutical industry has indigenous technological and productive capabilities to meet up to 70 per cent of the domestic requirement of bulk drugs and almost all the demands for formulations 2 . Its cost-effective technological capabilities not only restrict imports from developed countries into India, but also generate rising trade surpluses in pharmaceutical products by exporting to over 65 countries 3 . In a sense, India has emerged as a major developing country competitor in the world pharmaceutical market.
With over 16000 pharmaceutical units, Indian pharmaceutical industry is one of the largest and most advanced among developing countries that produces life-saving drugs belonging to all major therapeutic groups at a fraction of prices existing in the world market. The industry today possesses the largest number of US Food & Drug Administration (USFDA) approved manufacturing facilities outside the US and has been filing more number of Drug Master Files (DMFs) with the USFDA for drug exports to the US than that filed by Spain, Italy, China and Israel taken together 4 . Considering the 1950s period when India hardly had any base in pharmaceutical sector, these achievements are truly remarkable for a developing country. The role of strategic government policies has clearly been critical in local technological developments that took place in Indian pharmaceutical industry. These government policies led the initial capability formation to produce modern drugs locally by establishing public-owned companies and allowed reverse engineering-based technological change for domestic private-owned companies.
However, the setting of technological developments adopted by Indian companies was lopsided. Local innovation has been mostly limited to cost-effective process development and firm-specific R&D (Research & Development) strategy grossly neglected new product developments. While weaker intellectual property rights stimulated process innovation by Indian companies in the past but in subsequent period they emerged as an important obstacle to advance technological developments and learning. With globalization and liberalization, Indian pharmaceutical firms are increasingly forced into world market and their inadequate product development capabilities are likely to marginalize their future growth and expansion. In this backdrop, the role of outward FDI can be instrumental for Indian firms to overcome this particular limitation in their innovation strategy. Through overseas acquisitions Indian pharmaceutical firms can quickly enlarge their product portfolios and intangible asset bundle by adding new technologies, managerial and marketing skills.
This paper has examined the ways by which outward FDI can help Indian pharmaceuticals firms to overcome their inadequate capabilities for product innovation. Section 2 explores the main mechanisms through which India has built its technological base in the pharmaceutical sector and spell out how they have restricted innovation activities of Indian firms to just process developments. Besides considering the technological benefits that overseas acquisitions have on acquiring Indian pharmaceutical firms, Section 3 focuses on trends and geographical pattern of Indian pharmaceutical OFDI. It also presents a series of short case studies related to five largest acquirers from Indian pharmaceutical sector. These case studies primarily based on company annual reports, company press releases and newspaper reports seek to identify the main motivations of acquisitions that are available from managerial comments and perspectives. These case studies are to address the basic question of this paper: Are Indian pharmaceutical companies using overseas acquisition to overcome their limited product development technological capabilities? Section 4 concludes the paper.
Developing local technological capability
In the initial period during 1950s-60s, the Indian pharmaceutical industry was largely dominated by foreign enterprises and possessed hardly any local productive capability based on indigenous raw materials. Foreign firms, enjoying a strong patent protection under the Patent and Designs Act 1911, were averse to local production and mostly opted for imports from home country as working of the patent. The absence of domestic competition and product patent regime provided foreign firms with abnormal monopoly power to charge higher prices for their drugs. Foreign firms even with their shallow specialization centered on trading activities could reap extraordinary profits (Rs. 600 crore annual sales for an investment of less than a few crore!) (Joseph, 1979) . Further, these foreign firms tend to operate in lucrative pharmaceutical segments rather than meeting demand for essential life saving drugs. While the existing product patent regime arrested the potential of local knowledge developments via incremental innovation, general Indian population suffered most during this period under the consistent scarcity of essential medicines and surging drug prices.
These adverse situations, namely inadequate technological capabilities of the domestic sector to start local production and hesitation of foreign firms to do so, called for active policy interventions and the Indian government decided to intervene through direct public sector investment. This led to the establishment of the Indian Drugs and Pharmaceuticals Ltd. (IDPL) plants at Rishikesh and Hyderabad in 1961 and the Hindustan Antibiotics at Pimpri, Pune, in 1954 to manufacture penicillin. The starting of the public sector enterprises has been an important step towards scaling up indigenous technological capability of Indian pharmaceutical sector as they assumed the initiative in producing bulk drugs indigenously and led to significant knowledge spillovers on the domestic private sector. In addition, government has initiated building national institutions for creating scientific, managerial and general skills, which shall be readily and cheaply available to the industry for productive purposes.
The positive role of direct public sector investment in local technological progress has been complemented by the enactment of the Indian Patent Act (IPA) 1970 and the New Drug Policy (NDP) 1978 in the 1970s. The IPA 1970 brought in a number of radical changes in the patent regime by reducing the scope of patenting to only processes and not pharmaceutical products and also for a short period of seven years from the earlier period of 16 years. It also recognizes compulsory licensing after three years of the granting of the patent. The enactment of the process patent regime contributed significantly to the local technological development via adaptation, reverse engineering and new process development (Aggarwal, 2007; Pradhan and Alakshendra, 2006) . As there exists several ways to produce a drug, domestic companies innovated cost-effective processes and flooded the domestic market with cheap but quality drugs. This led to the steady rise of the domestic firms in the market place. The NDP 1978 has increased the pressure on foreign firms to manufacture bulk drugs locally and from the basic stage possible. Foreign ownership up to 74 per cent under the Foreign Exchange Regulation Act (FERA) 1973 was permitted to only those firms producing high technology drugs. Foreign firms that are simply producing formulations based on imported bulk drugs were required to start local production from the basic stage within a two-year period. Otherwise, they were required to reduce their foreign ownership holding to 40 per cent. New foreign investments were to be permitted only when the production involves high technology bulk drugs and formulations thereon.
The outcome of the strategic government interventions in the form of a soft patent policy and a regime of discrimination against foreign firms affected the industry with a time lag and provided strong growth impetus to the domestic sector during 1980s. Domestic enterprises based on large-scale reverse engineering and process innovation achieved near self-sufficiency in the technology and production of bulk drugs belonging to several major therapeutic groups and developed modern manufacturing facilities for all dosage forms like tablets, capsules, liquids, orals and injectibles. These had a lasting impact on the competitive position of the domestic firms in the national and international markets. In 1991, domestic firms have emerged as the main players in the Indian market with about 70 and 80 per cent market shares in the case of bulk drugs and formulations respectively (Lanjouw, 1998) . The industry turns out to be one of the most export-oriented sectors in Indian manufacturing with more than 30 per cent of its production being exported to foreign markets (Pradhan, 2007) . The trade deficits of the seventies have been replaced by trade surpluses during 1980s.
Although the Indian policy regime has succeeded in building local capability in pharmaceutical sector but it has also created a number of limitations in pushing forward firm's productivity and technological activities (Figure-1) . It is noteworthy that Indian domestic pharmaceutical companies now have advantage of innovative cost-effective processes, discovery in novel drugs delivery system, self-reliance in producing quality raw materials and production led by quality management. However, these technological strengths are confined to a small group of large Indian pharmaceutical companies. Indian pharmaceutical industry hosts a total of 16326 units of which just 123 units are large-sized (Pradhan and Sahu, 2008) . Clearly, majority of the Indian pharmaceutical companies suffered from limitation of financial, technical and skill resources to undertake any kind of R&D activities. It is estimated that R&D-doing firms constitute about just 18 per cent among small pharmaceutical firms whereas they respectively account for 32 and 52 per cent among large-and medium-sized pharmaceutical firms during [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] . Notably, the R&D intensity of large firms has gone up significantly from 0. Adding to the limitation of a small number of Indian pharmaceutical firms undertaking R&D is the fact that such R&D expenses are not only of minimal amount, but have also been predominantly for process technological activities. The process patent regime that remained in place throughout 1972-2005 incentivized the process of technological change in a narrow range to improvements in production process, raw material and intermediate inputs. Indian companies had little inducement to undertake research for product developments as other Indian companies can legally launch any new product by simply resorting to another new process. As a result, firm-level capability in product developments was significantly undermined and for a long time. With cost-effective processes, Indian companies have focused on the low end of value-chains in pharmaceuticals like producing generics than opting for branded products or supplying bulk drugs to global players than market formulations of their own. Moreover, the fragmented domestic markets protected from external competition have actually ushered an era of price competition in the domestic market, which was essentially achieved via new cost-efficient process rather than the non-price competition based on quality and frontier innovation. Limited innovation or incremental innovation alone defines the criteria for firms' survival and growth under the contemporary protected domestic market and process patent regime.
However, the weakness of this limited innovation strategy for firm growth is quite obvious with the implementation of liberalization measures with regard to the Indian pharmaceutical industry like permission to 100 per cent inward FDI under automatic route and widespread import tariff reductions on pharmaceutical products and machinery. The competition faced by Indian pharmaceutical firms is increasingly globalizing with competitive sources shifting from low price advantage to those based on product innovation, quality, skill and product differentiation. The adoption of product patent regime by India in mid-2000s required that Indian firms now adopt new forms of innovation, i.e. product innovation if they like to survive. The growing competition also requires them to expand their market focus from local to overseas markets.
OFDI to overcome innovation limits
With markets and competition getting globalized, the innovation strategy of Indian pharmaceutical firms require a major transformation with increasing focus on quality and product development, which were hitherto neglected. They are urgently required to set up inhouse R&D centre and allocate substantial financial and skill resources for both process and product developments to face imminent competitive challenges. Such product-oriented R&D investments are not only risky, but also involve long gestation period with uncertain outcome. Apparently, the route of high cost in-house R&D for enlarging product portfolio is a suitable long-term technological strategy for Indian pharmaceutical firms but would obviously not serve their purpose of meeting imminent competitive pressures being unleashed by liberalizing policies.
In this context, outward FDI can allow Indian pharmaceutical firms to overcome their most important innovation limit of inadequate product development capability. Indian firms rather putting their scare resources in long-term high-cost innovation strategy can simply acquire foreign companies with new product portfolio and advance technologies. Such strategic assetseeking OFDI immediately upgrade acquiring firms to a higher scale of technological specialization and diversification and offer a way to overcome entry barriers that exist in accessing developed countries markets. Added to these positive spinoffs, acquiring Indian firms are likely to derive immediate market expansion, economies of technological and business synergies, and to access new marketing skills, overseas sales distribution networks, and organizational knowledge (Figure-2 ).
Figure-2: Possible Effects of Outward FDI
The physical presence of Indian companies through greenfield and brownfield OFDI in innovative developed countries also provide opportunities for considerable technological and organizational learning simply because of proximity to innovative competitors. Indian pharmaceutical firms can absorb knowledge-spillovers from large scale R&D activities that are actually going on in developed countries and global market pressures shall in turn keep them on the path of constant learning and technological improvements.
Recently, a number of Indian firms are realizing that building sustainable competitive advantage in global markets requires more than just undertaking greenfield OFDI to exploit ownership advantages based on process technologies. Brownfield OFDI or acquisition is required to collect considerable knowledge on product developments and access trade-supporting infrastructure in foreign countries. As a result, they are now adopting an aggressive acquisition strategy with multiple firm-specific objectives like access to markets, products, technologies, marketing networks and to reap operating business synergies. Up to the end of 1990s, OFDI activities by Indian pharmaceutical firms have been largely in greenfield mode and since 2000 such activities are increasingly dominated by overseas acquisitions.
Emergence of Indian pharmaceutical OFDI
The emergence of Indian pharmaceutical OFDI can be traced back to two Nigerian joint venture OFDI projects undertaken by two Indian firms between 1977 and 1982-one established by Ranbaxy Laboratory Limited in 1977 and another by Unique Pharmaceutical Laboratories in 1982. Another four Indian companies, namely Ambalal Sarabhai Enterprises, Glenmark Pharmaceuticals, Lupin Laboratories and Hoechst India (a subsidiary of a German company) joined the OFDI process during 1983-89. Except one case of investment made by Ambalal Sarabhai Enterprises in UK, Indian pharmaceutical OFDI during 1977-1989 was confined to developing countries such as Nigeria, Malaysia, Nepal, Kenya, Indonesia and Thailand. The prevailing process technological advantages achieved by Indian pharmaceutical firms under the liberal patent regime appear to be the central force behind their OFDI activities. They were motivated to exploit their ownership advantages based on cost-effective process innovation in other developing countries having liberal patent policies.
With the growing process technological capability of Indian firms and off-patenting of many modern drugs since 1990, Indian pharmaceutical OFDI assumed greater scale and high degrees of geographical specialization in 1990s. A total of 61 Indian pharmaceutical companies undertook US $212 million worth of investment in 43 host countries in the 1990s (Table-1, Figure-3 ). Nearly 36 per cent of this aggregate investment has gone into developing countries. During this period a shift in the Indian policy regime occurred that allowed global competition into the pharmaceutical sector through inward FDI and imports of drugs. New competitive pressures in turn forced Indian pharmaceutical firms to expand their market focus and to improve their technological profile to include product development capability. The forthcoming product patent regime in 2005 and compulsory adoption of good manufacturing practices further diminished the traditional importance of process development capabilities in firms' survival and growth strategy. This made Indian pharmaceutical firms more conscious about the importance of global markets and new sources of competitiveness like quality, product development capabilities and constant innovation in management system.
The period 2000-07 witnessed a sharp rise in the size of outward Indian pharmaceutical investment led by an increasing number of Indian parent companies. Unlike in the past, a significant chunk of Indian pharmaceutical OFDI in early 2000s was to acquire new products and foreign knowledge to overcome existing limitations in their innovation strategy. From existing official sources, it is difficult to arrive at the magnitude of strategic asset-seeking OFDI in total pharmaceutical OFDI from India. The official statistics, among other limitations, capture only a part of total overseas acquisitions done by Indian firms (see Pradhan, 2008 for more detail). As the majority of overseas acquisitions concluded by Indian firms is led by substantial resource mobilization from overseas sources including foreign affiliates of Indian firms, Indian official sources only include a part of finance that Indian parent companies transfer from India to abroad for acquisition. Therefore, the estimated US $2.7 billion pharmaceutical outward FDI obtained from different official statistics has been termed as greenfield in Table- 1. Given the imperatives of Indian pharmaceutical firms to expand their market size and acquire firm-specific assets, it is not surprising that overwhelmingly Indian pharmaceutical FDI during 2000-07 has gone into innovative developed countries with large-sized pharmaceutical market. Developed region hosts as high as 88 per cent of Indian pharmaceutical FDI in this period. The relative significance of pharmaceutical OFDI in Indian manufacturing OFDI is also quite substantial for recent periods. Unlike pre-1990s period where Indian pharmaceutical firms contributed minimal amount, but have accounted remarkably higher share at 33 per cent in 2000-07 ( Figure-3 ). (Table-3 ). Developed region with 82.6 per cent share in total acquisition value is clearly the leading host location for these acquisition activities. Such concentration of Indian pharmaceutical acquisitions in developed region is indicative of the trend that Indian pharmaceutical firms were compelled to use acquisition as a strategy to overcome their prominent innovation limit, namely inadequate product development capabilities. Skillintensive and R&D-oriented developed countries are thus emerging as attractive destinations for Indian firms seeking new products and new markets. 
Cases of leading Indian acquirers
Table-4 presents 13 leading overseas acquirers from Indian pharmaceutical industry. Most of these acquiring Indian firms are industry leaders in India. Their emergence and growth have co-evolved with numerous public policies to support the domestic sector like starting of public sector drugs companies, government research laboratories, adoption of process patent regime, fiscal incentives for indigenous R&D, etc. These firms through substantial knowledge creation in new process development outcompeted dominant foreign players to emerge as key players in the domestic market and to build their internationalization strength through exporting.
With the implementation of new technological policy regime warranted by TRIPs in the home country and traditional export markets, these Indian domestic firms realized that their existing process-oriented technological capabilities are not adequate enough for meeting global competitive challenges. Three amendments to Indian Patent Act in 1999, 2002 and 2005 respectively provided for the provision of exclusive marketing rights, extension of patent duration to 20 years with reversion of burden of proof from patentee to defendant in issues of process patent infringement, and introduction of product patent protection.
In view of these changes in regulatory regime, the focus of leading Indian pharmaceutical firms started shifting from knowledge creation for new process to new product and brand. It is not surprising that these firms have chosen overseas acquisition as a strategy to achieve multiple objectives of new markets and new products. The broad range of their acquisition activities involved product and brand acquisitions, world-class manufacturing facilities and taking over of companies with significant intangible assets like products and technologies. This strategic assetseeking objective of leading acquiring Indian firms can be seen from short cases of five individual companies, which are discussed below.
Ranbaxy Laboratories Ltd 5 .
Ranbaxy Laboratories is the most aggressive overseas acquirer from Indian pharmaceutical sector with 11 acquisition deals spread across 10 countries. The company was early to recognize the imperative of TRIPS regime and inadequacy of its process development capabilities accumulated under an inward-looking development strategy. In his message to the shareholders of the company, Mr. Tejendra Khanna, Chairman, Ranbaxy Laboratories emphasized this fact very clearly: Apart from undertaking necessary reorientation of its in-house research activities to include product development, Ranbaxy has used acquisition as a strategy to simultaneously access new products and new markets. In September 1995, it has acquired Ohm Laboratories with the basic objective of accessing latter's advanced manufacturing capabilities and technological processes to create quality branded and generic OTC products. According to the company press release, this acquisition has offered "a comprehensive development scale up and manufacturing of a diversified line of over-the-counter and Rx generic pharmaceuticals In continuation of its acquisition strategy, Ranbaxy Laboratories entered into an agreement to buy France-based RPG (Aventis) SA along with its fully owned subsidiary, OPIH SARL, in December 2003 7 . With this acquisition Ranbaxy Laboratories became the fifth largest generic player in France and got access to strong brand equity of the acquired unit and its strong product portfolio covering 52 molecules 8 . To further strengthen its product portfolio, Ranbaxy Laboratories acquired a generic product portfolio consisting of 18 products belonging to the Spanish pharmaceutical company Efarmes SA in June 2005. Ranbaxy Laboratories' Regional Director for Europe, CIS & Africa, Mr. Peter Burema described the significance of this acquisition as follows:
"The acquisition fortifies our presence in Spain while augmenting our existing product portfolio. With this strategic development, we will be able to provide a wide range of quality generics to meet the growing needs of patients in this part of the world 9 ."
The year 2006 has been a watershed year for acquisition strategy of Ranbaxy Laboratories with as many as five overseas acquisitions. In March 2006, Ranbaxy Laboratories acquired Allen generic business from GlaxoSmithKline in Italy and one generic company each in Romania and Belgium. The product portfolio acquisition is a route to fast track growth in Italy with Ranbaxy Laboratories deriving strong advantages from product complementarities in the short term and catering to the business opportunities that will be thrown open by future patent expiries 10 . The acquisition of Terapia is an important strategy for acquiring new knowledge and strong market presence in Europe. The acquired unit had strong distribution and marketing network in the Romanian pharmaceutical market with a wide range of portfolio and new product pipeline, excellent R&D capabilities, world class in-house bioequivalence facilities and low cost manufacturing facilities. The underlying desire of the company to broaden its geographical operation and global manufacturing scale led it to consistently pursue the route of overseas acquisition. In October 1999, the company acquired a soft gelatin capsule manufacturing plant in New Jersey, USA. This acquisition has added substantial manufacturing capabilities to allow Stride Arcolab to be a major player in the international soft gelatin market. In 2001-02, the company undertook a total of three foreign acquisitions targeted at Brazil and Mexico. It has acquired 52 per cent stake in Solara Farmaceutica to enter into the fast growing Mexican market. This acquisition provided access to a state-of-the-art commissioned manufacturing facility by Solara for tablet and capsules. 
Glenmark Pharmaceuticals Ltd.
The third largest overseas acquirer from Indian pharmaceutical sector is Glenmark Pharmaceuticals with a total of 8 acquisition deals. The company was very early to appreciate the role of acquisition in creating essential capabilities for the challenges thrown up by product patent regime and global competition. The 1999-2000 Annual Report of the company explicitly mentioned acquisition as a potential growth strategy: "In its onward growth, Glenmark will continue to consider appropriate company and brand acquisition opportunities to enhance its portfolio" (pp. 8).
Its first overseas acquisition was the Brazil-based Laboratorios Klinger in April 2004.
The acquired entity had 21 approved product registrations in Brazil covering braded generics and OTC products. This acquisition was overwhelmingly a market entry strategy into the largest pharmaceutical market in South America and to quickly enhance market presence. In August 2004, Glenmark acquired two FDA approved products from Clonmel Healthcare Ltd. As per Jeffrey Weiss, CEO, Glenmark Pharmaceutical Inc, this acquisition will accelerate Glenmark's product growth plan in the US 18 . In March 2005, it acquired the exclusive manufacturing and marketing global rights of a leading hormonal brand, Uno-Ciclo from Instituto Biochimico Indústria Farmacêutica Ltda. Mr. Glenn Saldanha, Managing Director and CEO of Glenmark Pharmaceutical further emphasized this product acquisition strategy as:
"The purchase of Uno-Ciclo is another step towards enhancing our product basket and extending our reach in Brazil and the Latin American region".
The acquisition of Servycal SA-an Argentine marketing company with a basket of 17 approved product registrations and additional three products pending registration-in October 2006 represent Glenmark's direct entry strategy into Argentina. Apart from accessing Servycal's strong retail and hospital presence in Argentina, this acquisition enhances Glenmark's geographical presence in 12 other South American country markets where Servycal's products are registered 19 . To further expand its geographical spread and width of product offerings, it has acquired Bouwer Bartlett Pty-a South African sales and marketing company in December 2005. Mr. Glenn Saldanha offered following comment on this acquisition 20 :
"The purchase of Bouwer Bartlett is part of our long-term strategy to emerge as a speciality/brand company marketing novel drugs, by acquiring front-ends in key markets outside the USA, the EU and Japan."
The year 2006 saw Glenmark acquiring new product than acquisition of companies or manufacturing assets. To accelerate its product-focused generics presence in the US market, Glenmark acquired manufacturing and marketing rights of 2 liquid generic pharmaceutical products from Lehigh Valley Technologies Inc. and another 3 generic controlled-substance pharmaceutical products from Aspen USA Inc. in May 2006. Another 7 products of Lehigh Valley Technologies targeted at the US market were acquired by the company in December 2006. In June 2006, it has acquired global intellectual property rights of 7 products and 11 presentations from P D Pharmaceuticals (Pty), South Africa.
In March 2007, Glenmark acquired the company Medicamenta to get its first commercial foothold into the strategically important market of Europe. The acquitted entity with its basket of 29 products has significant branded presence and strong sales and marketing operations in both Czech Republic and Slovakia. The President of Glenmark Europe, Guy Clark, while describing this acquisition has stated: "This is the first of many steps that Glenmark will take on its journey to build a significant branded presence in the important market of Europe, and Medicamenta will also provide a geographically central base to support Glenmark's other European distribution activities."
In July 2007, Glenmark acquired two new biological entities (NBE) from Canada-based Chromos Molecular Systems Inc to expand and diversify its product portfolio.
Sun Pharmaceutical Industries Ltd.
By 1990s, Sun Pharmaceutical with its strategy of serving niche high-margin market segments such as psychiatry and central nervous system drugs gained a good presence in the domestic market. The second half of 1990s witnessed Sun Pharmaceutical adopting a series of domestic acquisition to enlarge its product range and manufacturing capacity to emerge as a national player. After achieving rapid expansion in national market, Sun Pharmaceutical saw the emerging generics opportunities in the US and decided to extend its acquisition strategy to cover this overseas market.
Caraco Pharmaceutical Laboratories-a Detroit based manufacturer of generic pharmaceuticals is the first overseas acquisition made by Sun Pharmaceutical. This acquisition was an entry strategy into the lucrative US generics market and was completed in successive equity stake enhancement in 1997, 2002, 2003 and 2004 . Sun Pharmaceutical viewed Caraco as a vehicle to get USFDA approval for its own generic products in the US and market introduction. The acquisition of three niche brands from the US-based Women's First Healthcare in September 2004, marked Sun Pharmaceutical's initial attempt in the US branded generic space. In 2005, it has acquired Valeant Pharmaceuticals' Ohio manufacturing facility and US-based Able Laboratories. The Ohio manufacturing facility is expected to help Sun Pharmaceutical in reaping emerging opportunities in liquids and semi-solids like creams and ointments and in speeding up filings for the US generic market. By acquiring the rights to entire product line that were being marketed by Able Laboratories and its dosage-form manufacturing facilities, Sun Pharmaceutical has significantly expanded its US operation.
Sun Pharmaceutical expanded its global manufacturing base by acquiring Hungary-based Valeant's raw materials and dosage-form manufacturing operations in August 2005. This became Sun Pharmaceutical's first European manufacturing base. In May 2007, it entered into definitive agreements to acquire Israel-based Taro Pharmaceutical Industries with established subsidiaries, manufacturing facilities and products across the US, Canada, Israel and Ireland. The acquired entity has strong product baskets in dermatology, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories and possesses world-class manufacturing facilities with necessary regulatory approvals in operating markets. In the US market it has more than 100 ANDA (Abbreviated New Drug Application) approvals from USFDA with additional 26 ANDAs awaiting approval. By July 2008, Sun pharmaceutical has already acquired 36 per cent stake in Taro and has initiated a hostile bid to acquire additional 12 per cent stake from controlling shareholders in July 2008. Clearly, the foregoing brief reviews on the experience of selected Indian pharmaceutical companies do indicate that they are using overseas acquisitions to expand their global market presence in addition to getting access to new products, marketing and managerial skills, and quality standards. With this newly gained knowledge they are expected to overcome their existing innovation barrier such as small size of their product portfolio primarily nurtured through process technological activities in the home country. In case these Indian pharmaceutical firms are able to integrate acquired new knowledge and efficiently absorb them for further knowledge developments, this overseas acquisition wave from India will have profound effects on both home and host countries. India will witness the emergence of truly global Indian firms based on advance knowledge and host countries are likely to benefit from supply of costeffective life-saving drugs and generics by Indian companies.
Concluding Remarks
Initial constraints of being a developing country and non-existent productive base in modern pharmaceutical sector notwithstanding, India could build a very competitive pharmaceutical industry. The strategic government policies including public sector drug production, adoption of short duration process patent regime and strong monitoring of activities of foreign companies, resulted in significant growth of domestic investment in the pharmaceutical sector and increased local technological activities mainly in the form of costeffective process development. This led to rising domestic productive capacity to satisfy growing demand for drugs and prompted a consistent export surge to overseas markets.
It is since 1990s the issue of a broad-based innovation strategy for long run growth of Indian pharmaceutical firms started attracting corporate and expert attention. The liberalization measures and a product patent regime made it imperative that Indian pharmaceutical firms must enlarge their innovation strategy towards product oriented R&D. Indian pharmaceutical firms without enhancing in-house capabilities to enlarge product portfolio are going to face more survival challenges in coming years. Many capable Indian pharmaceutical companies are early to realize these challenges and have gone for suitable measures like putting more resources for product and process development. In addition, they have also opted for overseas acquisition as a favourite strategy to overcome their inadequate product development and other intangible capabilities. Thus, the recent boom in overseas acquisitions by Indian pharmaceutical firms represents the strategic motivation of acquiring new products, new markets, skills and technologies. Brief case studies of five acquirers from Indian pharmaceutical sector further testify the desire of Indian companies to improve their competitive advantages by accessing new technologies and products. In this sense overseas acquisition can be seen as a means of overcoming limited product development capabilities that characterizes majority of Indian pharmaceutical companies.
Although overseas acquisition can be important for enhancing firm-specific technological capabilities and for entering into new markets, they are also challenging for acquiring Indian pharmaceutical firms in a number of ways. Investment requirements in acquisition are quite substantial and not all Indian pharmaceutical firms have access to such resources. Especially, small-and medium-sized pharmaceutical units that dominate the Indian pharmaceutical industry shall not be able to benefit from the acquisition strategy. They don't have financial, technological and skill resources to undertake overseas acquisition to improve their product portfolio. Therefore, the scope and opportunities that are associated with acquisition strategy are limited to relatively large Indian pharmaceutical companies.
Since Indian pharmaceutical companies are new to global production, overseas acquisition involves significant market and operational risks. In the preparatory stage, the challenge is to decide on target markets and to identify target companies that can fit well into the requirements of Indian acquiring companies. In addition, Indian firms are required to determine the transaction value, negotiate with potential target companies and obtain information related to host country legal and environment clearances. Although financial accounting and consultancy firms help in these efforts, Indian firms should have adequate in-house skills to manage these issues more realistically. Insufficient knowledge of host country laws, regulatory delays, strong legal monitoring in host developed countries related to manufacturing process and quality of drugs and unexpected changes therein, rapid changes in demand and prices, growing competition, etc., represents high risk entail in overseas acquisition.
After acquisition, an Indian firm faces operational challenge to carry forward acquired production activities in foreign countries. The immediate issue is the post-acquisition integration that addresses the theme of harmonizing different work cultures, managerial practices, employment policies, etc., to successfully integrate the acquired overseas units and put it to efficient production. The scope for absorbing newly acquired foreign knowledge and benefiting from scale expansion clearly depends on the technological capabilities of acquirers themselves.
It is clear that without a well designed acquisition strategy, acquiring Indian pharmaceutical companies may not realize intended benefits from such activities. As long as Indian acquiring firms are aware of the potential risks involved in acquisition and well prepared to face such eventualities, overseas acquisitions can contribute to their greater geographical and economic diversification and upgrading of their technological capabilities significantly.
